<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01855048</url>
  </required_header>
  <id_info>
    <org_study_id>SAL200-1A</org_study_id>
    <nct_id>NCT01855048</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin® SAL200 in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Clinical Study to Evaluate the Safety, Pharmacokinetics and Phyarmacodynamcs of a Single Intravenous Dose of N-Rephasin® SAL200, in Healthy Male Valunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intron Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intron Biotechnology, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Objectives of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics&#xD;
      of single dose of N-Rephasin® SAL200 in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purposes of this study are to evaluate the pharmacokinetics, and pharmacodynamics and&#xD;
      safety of an experimental intravenous medication, N-Rephasin® SAL200 in healthy male.&#xD;
      Participants will include 36 male volunteers. Participants will be grouped according to&#xD;
      dosage of N-Rephasin® SAL200 including placebo (0 mg/kg). Study procedures include: check of&#xD;
      vital signs, reporting any experienced side effects, physical examination including&#xD;
      assessment of the cardiovascular system, and blood sample collection for monitoring of&#xD;
      pharmacokinetics, pharmacodynamics and antibody production etc. Participants will be involved&#xD;
      in study related procedures for up to 50 days after injection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 6, 2013</start_date>
  <completion_date type="Actual">February 7, 2014</completion_date>
  <primary_completion_date type="Actual">February 7, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the Safety of N-Rephasin® SAL200 in Healthy Human Volunteers</measure>
    <time_frame>Up to 50 days after administration</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Pharmacokinetic Parameters After Single IV Administration of N-Rephasin® SAL200 [Effective t1/2 (h)]</measure>
    <time_frame>0, 4, 8, 12, 16, 20, 24 hours post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamics Evaluation of N-Rephasin® SAL200 : Mean Concentration of Bactericidal Activity After Single Dose of N-Rephsin® SAL200 IV Administration</measure>
    <time_frame>up to 2hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic Evaluation of N-Rephasin® SAL200 at the Administered Doses by Analysis of Concentration of N-Rephasin® SAL200 in Serum [Cmax (µg/ml)]</measure>
    <time_frame>Day 1 to 2</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic Evaluation of N-Rephasin® SAL200 at the Administered Doses by Analysis of Concentration of N-Rephasin® SAL200 in Serum [Cmax/D (µg/ml/mg)]</measure>
    <time_frame>Day 1 to 2</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic Evaluation of N-Rephasin® SAL200 at the Administered Doses by Analysis of Concentration of N-Rephasin® SAL200 in Serum [AUC Last (µg*h/ml)]</measure>
    <time_frame>Day 1 to 2</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Anti-Bacterial Agents</condition>
  <condition>Methicillin-Resistant Staphylococcus Aureus</condition>
  <arm_group>
    <arm_group_label>N-Rephasin® SAL200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-Rephasin® SAL200, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INT200-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>N-Rephasin® SAL200</intervention_name>
    <description>continuous intravenous infusion over 60 minutes</description>
    <arm_group_label>N-Rephasin® SAL200</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>INT200-Placebo</intervention_name>
    <description>Formulation buffer for continuous intravenous infusion over 60 minutes</description>
    <arm_group_label>INT200-Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subject whose age is 20 ~ 45 at the time of screening visit.&#xD;
&#xD;
          -  Body weight of ≥50kg and &lt;90kg, while within ±20% of the ideal body weight. [ideal&#xD;
             body weight(kg) = {height(cm)-100}x 0.9]&#xD;
&#xD;
          -  Subject agreed to participate in the trial and to follow all of trial-related rules&#xD;
             with a full understanding, after having a full account of the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Present disease(s) or medical history(ies) which is(are) clinically significant on&#xD;
             liver, heart, nervous system, respiratory system, haemato-oncology, cardiovascular or&#xD;
             psychopathy.&#xD;
&#xD;
          -  Diagnosed or suspected infectious disease within 30 days in prior to the&#xD;
             administration.&#xD;
&#xD;
          -  Clinically significantly allergic to drug(s) containing AI of N-Rephasin® SAL200 or to&#xD;
             other drugs including aspirin and antibiotics, or has medical history(ies) on such&#xD;
             allergy.&#xD;
&#xD;
          -  Already has taken other drug(s) containing AI of N-Rephasin® SAL200.&#xD;
&#xD;
          -  Positive for Antibody of N-Rephasin® SAL200.&#xD;
&#xD;
          -  SBP≤90mmHg or DBP≤50mmHg, otherwise, SBP≥150mmHg or DBP≥100mmHg in Vital sign which&#xD;
             was measured after taking 3 minutes of resting in sitting position.&#xD;
&#xD;
          -  Has medical history of drug abuse or positive to drug abuse in urine drug screening.&#xD;
&#xD;
          -  Has taken any prescription drug(s) or herbal medicine(s) within 14 days prior to the&#xD;
             administration, otherwise, any OTC(Over the counter) (s) or vitamin(s) within 7 days&#xD;
             prior to the administration(However, can participate in the study if investigator&#xD;
             makes a decision that the subject can participate regardless the drug taken).&#xD;
&#xD;
          -  Has taken any other study drugs within 2 months prior to the administration.&#xD;
&#xD;
          -  Has donated blood(whole blood donation or component transfusion) within (2 months or 1&#xD;
             month, respectively) in prior to the administration, otherwise, has received blood&#xD;
             transfusion within 1 month in prior to the administration.&#xD;
&#xD;
          -  Smoke at present or positive to metabolism of nicotine in urine test.&#xD;
&#xD;
          -  Drink regularly(over 21 units/week, 1 unit= 10 g of pure alcohol), otherwise, is not&#xD;
             able to interrupt drinking and smoking in study period.&#xD;
&#xD;
          -  Investigator made a decision that the subject is not eligible based on results of&#xD;
             laboratory test or other reason.&#xD;
&#xD;
          -  Not agree with contraception for 60days after the administration, otherwise,&#xD;
             notification of pregnancy in case of his partner is pregnant for 90 days after the&#xD;
             administration.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In Jin Jang, M.D., Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://www.semanticscholar.org/paper/Guidance-for-Industry-Estimating-the-Maximum-Safe-Alert/8750b5d4c6564d44ac84826e3760f15ea0b836de</url>
    <description>FDA, Guidance for Industry, Estimating the Maximum Safe Starting Dose inInitial Clinical Trials for Therapeutics in Adult Healthy Volunteers, 2005.</description>
  </link>
  <results_reference>
    <citation>Loessner MJ. Bacteriophage endolysins--current state of research and applications. Curr Opin Microbiol. 2005 Aug;8(4):480-7. Review.</citation>
    <PMID>15979390</PMID>
  </results_reference>
  <results_reference>
    <citation>Fischetti VA. Bacteriophage lysins as effective antibacterials. Curr Opin Microbiol. 2008 Oct;11(5):393-400. doi: 10.1016/j.mib.2008.09.012. Epub 2008 Oct 14. Review.</citation>
    <PMID>18824123</PMID>
  </results_reference>
  <results_reference>
    <citation>Loeffler JM, Nelson D, Fischetti VA. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science. 2001 Dec 7;294(5549):2170-2.</citation>
    <PMID>11739958</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu JA, Kusuma C, Mond JJ, Kokai-Kun JF. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob Agents Chemother. 2003 Nov;47(11):3407-14.</citation>
    <PMID>14576095</PMID>
  </results_reference>
  <results_reference>
    <citation>Schellekens H. Immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2003 Jul;18(7):1257-9. Review.</citation>
    <PMID>12808158</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 3, 2013</study_first_submitted>
  <study_first_submitted_qc>May 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2013</study_first_posted>
  <results_first_submitted>June 16, 2021</results_first_submitted>
  <results_first_submitted_qc>October 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 3, 2021</results_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>N-Rephasin® SAL200</keyword>
  <keyword>endolysin</keyword>
  <keyword>Placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment have completed in a single center (Seoul National University Hospital) from Nov. 2013 and the completion date is Feb. 2014.</recruitment_details>
      <pre_assignment_details>57 subjects were screened and 36 subjects met the eligibility criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>INT200-Placebo</title>
          <description>Placebo&#xD;
INT200-Placebo: Formulation buffer for continuous intravenous infusion over 60 minutes</description>
        </group>
        <group group_id="P2">
          <title>N-Rephasin® SAL200, 0.1mg/kg</title>
          <description>N-Rephasin® SAL200: continuous intravenous infusion over 60 minutes</description>
        </group>
        <group group_id="P3">
          <title>N-Rephasin® SAL200, 0.3 mg/kg</title>
          <description>N-Rephasin® SAL200: continuous intravenous infusion over 60 minutes</description>
        </group>
        <group group_id="P4">
          <title>N-Rephasin® SAL200, 1 mg/kg</title>
          <description>N-Rephasin® SAL200: continuous intravenous infusion over 60 minutes</description>
        </group>
        <group group_id="P5">
          <title>N-Rephasin® SAL200, 3 mg/kg</title>
          <description>N-Rephasin® SAL200: continuous intravenous infusion over 60 minutes</description>
        </group>
        <group group_id="P6">
          <title>N-Rephasin® SAL200, 10 mg/kg</title>
          <description>N-Rephasin® SAL200: continuous intravenous infusion over 60 minutes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>one subject in the 1 mg/kg dose group was 171.3 cm in height and weighed 81 kg at the screening, indicating that this subject was not within the range of ideal body weight (51.3-77.0 kg) for the subject's height, but the subject was enrolled in the study. The investigators judged that that subject was not at increased risk of adverse events in comparison with other subjects. Subject completed the remaining study procedures as scheduled in the study protocol without showing adverse events.</population>
      <group_list>
        <group group_id="B1">
          <title>N-Rephasin® SAL200 0.1(mg/kg)</title>
          <description>N-Rephasin® SAL200, 0.1 mg/kg&#xD;
N-Rephasin® SAL200: continuous intravenous infusion over 60 minutes</description>
        </group>
        <group group_id="B2">
          <title>N-Rephasin® SAL200 0.3(mg/kg)</title>
          <description>N-Rephasin® SAL200, 0.3 mg/kg&#xD;
N-Rephasin® SAL200: continuous intravenous infusion over 60 minutes</description>
        </group>
        <group group_id="B3">
          <title>N-Rephasin® SAL200 1(mg/kg)</title>
          <description>N-Rephasin® SAL200,&#xD;
1 mg/kg&#xD;
N-Rephasin® SAL200: continuous intravenous infusion over 60 minutes</description>
        </group>
        <group group_id="B4">
          <title>N-Rephasin® SAL200 3(mg/kg)</title>
          <description>N-Rephasin® SAL200, 3 mg/kg&#xD;
N-Rephasin® SAL200: continuous intravenous infusion over 60 minutes</description>
        </group>
        <group group_id="B5">
          <title>N-Rephasin® SAL200 10(mg/kg)</title>
          <description>N-Rephasin® SAL200, 10 mg/kg&#xD;
N-Rephasin® SAL200: continuous intravenous infusion over 60 minutes</description>
        </group>
        <group group_id="B6">
          <title>INT200-Placebo</title>
          <description>Placebo&#xD;
INT200-Placebo: Formulation buffer for continuous intravenous infusion over 60 minutes</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="9"/>
            <count group_id="B7" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.3" lower_limit="25" upper_limit="26"/>
                    <measurement group_id="B2" value="27.8" lower_limit="23" upper_limit="33"/>
                    <measurement group_id="B3" value="29.8" lower_limit="23" upper_limit="39"/>
                    <measurement group_id="B4" value="23.7" lower_limit="20" upper_limit="27"/>
                    <measurement group_id="B5" value="30.5" lower_limit="24" upper_limit="38"/>
                    <measurement group_id="B6" value="26.2" lower_limit="22" upper_limit="29"/>
                    <measurement group_id="B7" value="27.4" lower_limit="20" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.1" lower_limit="64.1" upper_limit="72.2"/>
                    <measurement group_id="B2" value="65.5" lower_limit="54.9" upper_limit="76.2"/>
                    <measurement group_id="B3" value="74.0" lower_limit="67.6" upper_limit="80.5"/>
                    <measurement group_id="B4" value="69.1" lower_limit="58.7" upper_limit="78.8"/>
                    <measurement group_id="B5" value="68.7" lower_limit="64.0" upper_limit="72.4"/>
                    <measurement group_id="B6" value="68.1" lower_limit="63.1" upper_limit="73.5"/>
                    <measurement group_id="B7" value="68.9" lower_limit="54.9" upper_limit="80.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176.8" lower_limit="171.2" upper_limit="181.2"/>
                    <measurement group_id="B2" value="171.3" lower_limit="165.2" upper_limit="175.9"/>
                    <measurement group_id="B3" value="175.1" lower_limit="171.3" upper_limit="179.8"/>
                    <measurement group_id="B4" value="174.8" lower_limit="171.3" upper_limit="177.3"/>
                    <measurement group_id="B5" value="170.5" lower_limit="163.7" upper_limit="178.6"/>
                    <measurement group_id="B6" value="174.5" lower_limit="169.8" upper_limit="179.3"/>
                    <measurement group_id="B7" value="173.6" lower_limit="163.7" upper_limit="181.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of the Safety of N-Rephasin® SAL200 in Healthy Human Volunteers</title>
        <time_frame>Up to 50 days after administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>INT200-Placebo, IV administration</description>
          </group>
          <group group_id="O2">
            <title>N-Rephasin® SAL200 (0.1 mg/kg)</title>
            <description>Study drug 0.0056 mL/kg, IV administration</description>
          </group>
          <group group_id="O3">
            <title>N-Rephasin® SAL200 (0.3 mg/kg)</title>
            <description>Study drug 0.017 mL/kg, IV administration</description>
          </group>
          <group group_id="O4">
            <title>N-Rephasin® SAL200 (1 mg/kg)</title>
            <description>Study drug 0.056 mL/kg, IV administration</description>
          </group>
          <group group_id="O5">
            <title>N-Rephasin® SAL200 (3 mg/kg)</title>
            <description>Study drug 0.167 mL/kg, IV administration</description>
          </group>
          <group group_id="O6">
            <title>N-Rephasin® SAL200 (10 mg/kg)</title>
            <description>Study drug 0.556 mL/kg, IV administration</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of the Safety of N-Rephasin® SAL200 in Healthy Human Volunteers</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Subjects with at least one AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Subjects with at least one drug-related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacokinetic Parameters After Single IV Administration of N-Rephasin® SAL200 [Effective t1/2 (h)]</title>
        <time_frame>0, 4, 8, 12, 16, 20, 24 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-Rephasin® SAL200 0.1mg/kg</title>
            <description>Study drug 0.0056 mL/kg, IV administration</description>
          </group>
          <group group_id="O2">
            <title>N-Rephasin® SAL200 0.3mg/kg</title>
            <description>Study drug 0.017 mL/kg, IV administration</description>
          </group>
          <group group_id="O3">
            <title>N-Rephasin® SAL200 1mg/kg</title>
            <description>Study drug 0.056 mL/kg, IV administration</description>
          </group>
          <group group_id="O4">
            <title>N-Rephasin® SAL200 3mg/kg</title>
            <description>Study drug 0.167 mL/kg, IV administration</description>
          </group>
          <group group_id="O5">
            <title>N-Rephasin® SAL200 10mg/kg</title>
            <description>Study drug 0.556 mL/kg, IV administration</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters After Single IV Administration of N-Rephasin® SAL200 [Effective t1/2 (h)]</title>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.02"/>
                    <measurement group_id="O2" value="0.04" spread="0.01"/>
                    <measurement group_id="O3" value="0.25" spread="0.05"/>
                    <measurement group_id="O4" value="0.38" spread="0.06"/>
                    <measurement group_id="O5" value="0.38" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacodynamics Evaluation of N-Rephasin® SAL200 : Mean Concentration of Bactericidal Activity After Single Dose of N-Rephsin® SAL200 IV Administration</title>
        <time_frame>up to 2hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-Rephasin® SAL200 0.1 mg/kg</title>
            <description>Study drug 0.0056 mL/kg, IV administration</description>
          </group>
          <group group_id="O2">
            <title>N-Rephasin® SAL200 0.3 mg/kg</title>
            <description>Study drug 0.017 mL/kg, IV administration</description>
          </group>
          <group group_id="O3">
            <title>N-Rephasin® SAL200 1 mg/kg</title>
            <description>Study drug 0.056 mL/kg, IV administration</description>
          </group>
          <group group_id="O4">
            <title>N-Rephasin® SAL200 3 mg/kg</title>
            <description>Study drug 0.167 mL/kg, IV administration</description>
          </group>
          <group group_id="O5">
            <title>N-Rephasin® SAL200 10 mg/kg</title>
            <description>Study drug 0.556 mL/kg, IV administration</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics Evaluation of N-Rephasin® SAL200 : Mean Concentration of Bactericidal Activity After Single Dose of N-Rephsin® SAL200 IV Administration</title>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0.13" spread="0.05"/>
                    <measurement group_id="O4" value="0.22" spread="0.10"/>
                    <measurement group_id="O5" value="0.40" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0.15" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0.04" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacokinetic Evaluation of N-Rephasin® SAL200 at the Administered Doses by Analysis of Concentration of N-Rephasin® SAL200 in Serum [Cmax (µg/ml)]</title>
        <time_frame>Day 1 to 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-Rephasin® SAL200 0.1mg/kg</title>
            <description>Study drug 0.0056 mL/kg, IV administration</description>
          </group>
          <group group_id="O2">
            <title>N-Rephasin® SAL200 0.3mg/kg</title>
            <description>Study drug 0.017 mL/kg, IV administration</description>
          </group>
          <group group_id="O3">
            <title>N-Rephasin® SAL200 1mg/kg</title>
            <description>Study drug 0.056 mL/kg, IV administration</description>
          </group>
          <group group_id="O4">
            <title>N-Rephasin® SAL200 3mg/kg</title>
            <description>Study drug 0.167 mL/kg, IV administration</description>
          </group>
          <group group_id="O5">
            <title>N-Rephasin® SAL200 10mg/kg</title>
            <description>Study drug 0.556 mL/kg, IV administration</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Evaluation of N-Rephasin® SAL200 at the Administered Doses by Analysis of Concentration of N-Rephasin® SAL200 in Serum [Cmax (µg/ml)]</title>
          <units>µg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.01"/>
                    <measurement group_id="O2" value="0.09" spread="0.04"/>
                    <measurement group_id="O3" value="0.82" spread="0.50"/>
                    <measurement group_id="O4" value="7.10" spread="5.39"/>
                    <measurement group_id="O5" value="55.99" spread="10.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacokinetic Evaluation of N-Rephasin® SAL200 at the Administered Doses by Analysis of Concentration of N-Rephasin® SAL200 in Serum [Cmax/D (µg/ml/mg)]</title>
        <time_frame>Day 1 to 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-Rephasin® SAL200 0.1mg/kg</title>
            <description>Study drug 0.0056 mL/kg, IV administration</description>
          </group>
          <group group_id="O2">
            <title>N-Rephasin® SAL200 0.3mg/kg</title>
            <description>Study drug 0.017 mL/kg, IV administration</description>
          </group>
          <group group_id="O3">
            <title>N-Rephasin® SAL200 1mg/kg</title>
            <description>Study drug 0.056 mL/kg, IV administration</description>
          </group>
          <group group_id="O4">
            <title>N-Rephasin® SAL200 3mg/kg</title>
            <description>Study drug 0.167 mL/kg, IV administration</description>
          </group>
          <group group_id="O5">
            <title>N-Rephasin® SAL200 10mg/kg</title>
            <description>Study drug 0.556 mL/kg, IV administration</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Evaluation of N-Rephasin® SAL200 at the Administered Doses by Analysis of Concentration of N-Rephasin® SAL200 in Serum [Cmax/D (µg/ml/mg)]</title>
          <units>µg/ml/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.001"/>
                    <measurement group_id="O2" value="0.005" spread="0.001"/>
                    <measurement group_id="O3" value="0.01" spread="0.01"/>
                    <measurement group_id="O4" value="0.03" spread="0.02"/>
                    <measurement group_id="O5" value="0.08" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacokinetic Evaluation of N-Rephasin® SAL200 at the Administered Doses by Analysis of Concentration of N-Rephasin® SAL200 in Serum [AUC Last (µg*h/ml)]</title>
        <time_frame>Day 1 to 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-Rephasin® SAL200 0.1mg/kg</title>
            <description>Study drug 0.0056 mL/kg, IV administration</description>
          </group>
          <group group_id="O2">
            <title>N-Rephasin® SAL200 0.3mg/kg</title>
            <description>Study drug 0.017 mL/kg, IV administration</description>
          </group>
          <group group_id="O3">
            <title>N-Rephasin® SAL200 1mg/kg</title>
            <description>Study drug 0.056 mL/kg, IV administration</description>
          </group>
          <group group_id="O4">
            <title>N-Rephasin® SAL200 3mg/kg</title>
            <description>Study drug 0.167 mL/kg, IV administration</description>
          </group>
          <group group_id="O5">
            <title>N-Rephasin® SAL200 10mg/kg</title>
            <description>Study drug 0.556 mL/kg, IV administration</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Evaluation of N-Rephasin® SAL200 at the Administered Doses by Analysis of Concentration of N-Rephasin® SAL200 in Serum [AUC Last (µg*h/ml)]</title>
          <units>µg*h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.005"/>
                    <measurement group_id="O2" value="0.05" spread="0.02"/>
                    <measurement group_id="O3" value="0.57" spread="0.31"/>
                    <measurement group_id="O4" value="7.26" spread="3.42"/>
                    <measurement group_id="O5" value="59.79" spread="9.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 50 Days ± 7 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>INT200-Placebo</title>
          <description>Placebo&#xD;
INT200-Placebo: Formulation buffer for continuous intravenous infusion over 60 minutes</description>
        </group>
        <group group_id="E2">
          <title>N-Rephasin® SAL200, 0.1mg/kg</title>
          <description>N-Rephasin® SAL200: continuous intravenous infusion over 60 minutes</description>
        </group>
        <group group_id="E3">
          <title>N-Rephasin® SAL200, 0.3 mg/kg</title>
          <description>N-Rephasin® SAL200: continuous intravenous infusion over 60 minutes</description>
        </group>
        <group group_id="E4">
          <title>N-Rephasin® SAL200, 1 mg/kg</title>
          <description>N-Rephasin® SAL200: continuous intravenous infusion over 60 minutes</description>
        </group>
        <group group_id="E5">
          <title>N-Rephasin® SAL200, 3 mg/kg</title>
          <description>N-Rephasin® SAL200: continuous intravenous infusion over 60 minutes</description>
        </group>
        <group group_id="E6">
          <title>N-Rephasin® SAL200, 10 mg/kg</title>
          <description>N-Rephasin® SAL200: continuous intravenous infusion over 60 minutes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rigors</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Coughing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jun SooYoun, Ph.D. / Executive Director/ Principal researcher</name_or_title>
      <organization>Organization:Institute of iNtRON Biotechnology</organization>
      <phone>+82-31-739-5332</phone>
      <email>jsy@intron.co.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

